
Search
Selected Filter
Filter Results
Displaying 41–50 of 291 research results
-
Mar 7, 2022
Neurogene to Launch Gene Therapy Clinical Trial for Children with Batten Disease
The treatment will be delivered to the vitreous of the eye and ventricles of the brain
-
Feb 24, 2022
Second Sight Agrees to Merger to Maintain Retinal and Cortical Prostheses Programs
Company has been unable to meet revenue goals for the Argus II®
-
Feb 15, 2022
ProQR’s Phase 2/3 Clinical Trial for LCA10 RNA Therapy Doesn’t Meet Endpoints
The emerging treatment had shown encouraging results in a Phase ½ clinical trial
-
Feb 8, 2022
AGTC Plans Further Clinical Development of Achromatopsia (CNGB3) Gene Therapy
Interim results for pediatric patients with CNGB3 mutations were encouraging
-
Feb 1, 2022
Genentech-Roche Receives FDA Approval for Vabysmo for Treatment of Wet AMD and DME
This new treatment can reduce the frequency of injections into the eye
-
Jan 28, 2022
Kriya Therapeutics Licenses Emerging Foundation-Funded Dry AMD Gene Therapy
The Foundation Fighting Blindness is funding Bärb Rohrer, PhD, Medical University of South Carolina, to evaluate safety and efficacy of the gene therapy in a large animal model
-
Jan 19, 2022
ReNeuron Not Continuing Clinical Development of Cell-Based Therapy for RP
Company seeks to out-license its retinal progenitor therapy to a partner
-
Jan 18, 2022
Survey results will inform therapy developers and the agenda for a Patient-Focused Drug Development meeting with Food and Drug Administration representatives.
-
Jan 7, 2022
The company is currently developing programs for Stargardt disease (ABCA4), Usher syndrome, RP25 (EYS), and RP1.
-
Dec 17, 2021
ProQR Doses First Patients in Phase 2/3 Clinical Trials for its USH2A-Exon 13 RNA Therapy
The Sirius trial is for USH2A (exon 13 mutations) patients with advanced vision loss. The Celeste trial is for USH2A (exon 13 mutations) patients with moderate to early vision loss.